Case study looks at possible adverse reaction to popular COVID-19 drug
Sinai Health doctors say more research is needed on the popular antiviral drug Remdesivir after they documented a rare case of bradycardia in a male COVID-19 patient shortly after he received the medication.
Bradycardia, or an abnormally slow heart rate, is when the heart beats less than 60 times per minute. It can be life-threatening if the heart is unable to maintain a rate that pumps enough oxygen-rich blood throughout the body.
The case study, out today in the Canadian Medical Association Journal, highlights a potential rare and serious association between Remdesivir therapy and bradycardia observed in a Sinai Health patient.
Remdesivir has been shown to reduce the length of time moderately ill COVID-19 patients spend in hospital. It is approved by Health Canada for the treatment of hospitalized patients with COVID-19 pneumonia who require oxygen.
Globally, it is one of the most commonly used medications used to treat patients hospitalized with COVID-19, with more than two million doses estimated to have been administered worldwide during the pandemic.
“The bradycardia observed in our patient was suggestive of a probable adverse drug reaction,” said Dr. Day, adding there have been other similar cases recently described with the use of Remdesivir in COVID-19 patients. “This reinforces the need for further studies to explore whether this might be a rare drug reaction in this medication used frequently for patients with COVID-19 pneumonia.”
Risk factors for bradycardia include increasing age, cardiovascular disease, and the use of medications that can cause bradycardia, including beta blockers.